GLP-1 DRUGS — THE OZEMPIC TRUTH

The Weight Loss Miracle That Comes With a Biological Price Tag.

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) — are being prescribed to millions of UK adults and marketed as a revolution in metabolic medicine. The mechanism is real: mimicking glucagon-like peptide-1 to suppress appetite, slow gastric emptying, and improve insulin sensitivity. But the full biological picture is being systematically suppressed. Up to 40% of weight lost on these drugs is lean muscle mass. The drugs suppress appetite so profoundly that protein intake collapses. Rebound obesity upon cessation is near-universal. Pancreatitis, thyroid C-cell tumours, gastroparesis, and severe gastrointestinal side effects are documented. And every organ that produces GLP-1 naturally — gut L-cells stimulated by fibre, cold exposure, protein, and exercise — is being pharmacologically bypassed rather than biologically restored.